Table 2.
Clinical profile of snakebite among the study population
| Parameter | Frequency (Percentage) n = 100 |
|---|---|
| Snake species | |
| Krait | 40 |
| Cobra | 12 |
| Viper | 30 |
| Unknown | 18 |
| Bite site | |
| Upper limb | 37 |
| Lower limb | 63 |
| Whole blood clotting time >20 minutes | 84 |
| Bite-to-needle time | |
| <6 hours | 36 |
| 6–12 hours | 30 |
| 12–24 hours | 22 |
| >24 hours | 12 |
| Total ASV administration | |
| 10 vials | 4 |
| 20 vials | 35 |
| 30 vials | 61 |
| Duration of hospitalization | |
| <5 days | 28 |
| 5–10 days | 51 |
| >10 days | 21 |
| Complications/Outcome | |
| Cellulitis | 50 |
| Acute kidney injury | 34 |
| Septic shock | 12 |
| DIC | 10 |
| Respiratory failure | 10 |
| Non-survivors | 9 |
ASV, anti-snake venom; DIC, disseminated intravascular coagulation